• syeda hajrafatima
• Sanober yasmeen
• K.Shashikala
• V.Vijaya Sreedhar

Objective and background: Her-2/neu oncogene amplification has been implicated in the development and progression of many human cancers like breast cancer, pancreatic cancer and ovarian cancers and it is the target for therapeutic intervention with the help of humanized monoclonal antibody to Her-2/neu (Herceptin). Smaller studies suggest that Her-2/neu oncogene may be involved in the tumerogenesis of endometrial adenocarcinoma and targeting Her-2/neu may be beneficial for a selected group of patient showing Her-2/neu overexpression. The aim of this study was to evaluate Immunohistochemical (IHC) expression of Her-2/neu oncogene in endometrial carcinoma (EC) and its correlation with Histopathological features in order to define its potential prognostic value in Endometrial Carcinomas. Patients and methods: 42 Cases of Endometrial Carcinoma with stage I-IV were enrolled into this study. Demographic, clinical and pathologic information was obtained and recorded. Her-2/neu expression was evaluated by immunohistochemistry (IHC) on paraffin embedded tissue sections with Her-2/neu antibody. Overexpression was defined as complete, membrane, moderate to strong intensity staining in greater than 10% of cells. Results: Positive HER-2/neu expression is seen in 54.76% cases of endometrial carcinoma. Her-2/neu overexpression was associated in patients with advanced stage (p<0.01), High Grade (p<0.01), myometrial invasion (p<0.05), cervical invasion (p<0.01), and lymph node metastasis (p<0.01) but not associated with histological type of the Carcinoma (p >0.05). Conclusion: Our study demonstrated strong HER-2/neu overexpression in considerable proportion of the patients with Endometrial Carcinoma, higher rate HER-2/neu overexpression in patients with high grade, advanced stage, myometrial invasion, cervical invasion and lymph node metastasis, indicating Her-2/neu overexpression is related to most of the prognostic factors of Endometrial carcinoma thus suggesting HER-2/neu IHC can be incorporated into the criteria for determination of tumor aggressiveness as a prognostic marker and the use of anti-Her-2/neu (Herceptin) therapy in Patients harbouring Endometrial carcinoma with proven amplification or strong Her-2/neu overexpression.

Endometrial Carcinoma, Immunohistochemistry, Her-2/neu oncogene, Prognostic factor

"Immunohistochemical Expression of Her-2/Neu Oncogene in Endometrial Carcinoma and its relation with Histopathological Variables", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 6, page no.539-549, June 2019, Available :http://www.jetir.org/papers/JETIR1908079.pdf

"Immunohistochemical Expression of Her-2/Neu Oncogene in Endometrial Carcinoma and its relation with Histopathological Variables", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 6, page no. pp539-549, June 2019, Available at : http://www.jetir.org/papers/JETIR1908079.pdf